A single but durable stable disease sends the microcap's stock up 730%.
ApexOnco Front Page
Recent articles
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
Minghui’s MHB088C will soon start phase 3 in China.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
